Noida, Sep 1 (APAC Media): Shares of Symbiotec Pharmalab are set to make their debut on the stock exchanges on Tuesday, with grey market trends indicating a possible listing gain of nearly 20 per cent over the issue price.
The pharmaceutical company had fixed the price of its initial public offering (IPO) at Rs 988 per share. The stock was commanding a grey market premium (GMP) of around Rs 185-190 ahead of its listing, suggesting an indicative listing price of about Rs 1,173-1,178.
At these levels, investors who received an allotment could see a gain of around 19 per cent if the stock opens in line with grey market indications. However, the grey market is unofficial, and GMP trends do not necessarily translate into the actual listing price.
Symbiotec Pharmalab raised Rs 1,757 crore through its IPO. The issue comprised a fresh share sale of Rs 150 crore and an offer for sale (OFS) worth Rs 1,607 crore from existing shareholders.
The issue witnessed strong investor interest during the subscription period, adding to expectations of a firm debut on the exchanges.
Symbiotec Pharmalab operates in the pharmaceutical and biotechnology sector. The company’s investors, such as Rosewood Investments and Motilal Oswal’s India Business Excellence Fund-III, support the company.
Market participants will now focus on the company’s actual listing price and trading activity after the opening bell. While a strong GMP has raised expectations of a positive debut, the stock’s performance in the secondary market will depend on factors such as investor demand, valuation, earnings prospects and broader market conditions.
Grey market premiums can also change quickly in the days leading up to a listing and should therefore be viewed only as an indication of market sentiment rather than a guaranteed return.
The listing will provide investors with the first official market-based valuation of Symbiotec Pharmalab after its IPO and could set the tone for trading in the stock in the near term.
–ENDS–
Disclaimer:Â This article is for informational purposes only and is based on publicly available information. APAC Media is not responsible for investment decisions or losses. Please conduct your own research or consult a financial adviser before investing.
Also Read:
